Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D40GBC
|
|||
| Drug Name |
LY3526318
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Chronic low-back pain [ICD-11: MG30] | Phase 2 | [1] | |
| Company |
Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transformation-sensitive protein p120 (TRPA1) | Target Info | Antagonist | [2] |
| KEGG Pathway | Inflammatory mediator regulation of TRP channels | |||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05086289) Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain. U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.